Enhanced uptake of doxorubicin into bronchial carcinoma:β- glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site

Cancer Research

Volumn 57, Issue 12, 1997, Pages 2440-2445

  Mürdter, Thomas E ^a   Sperker, Bernhard ^a   Kivistö, Kari T ^a,e   McClellan, Monika ^b   Fritz, Peter ^b   Friedel, Godehard ^d   Linder, Albert ^d   Bosslet, Klaus ^c   Toomes, Heikki ^d   Dierkesmann, Rainer ^d   Kroemer, Heyo K ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b Pathologisches Inst am Robert B   (Germany)

^c SANOFI   (France)

^d Klinik Schillerhohe   (Germany)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; DOXORUBICIN; PRODRUG;

ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CYTOTOXICITY; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; LUNG CARCINOMA; LUNG PERFUSION; PRIORITY JOURNAL;

AGED; DOXORUBICIN; FEMALE; GLUCURONIDASE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PRODRUGS; TIME FACTORS;

EID: 14444281990     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Chabner, B. A., Allegra, C. J., Curt, G. A., and Calabresi, P. Antineoplastic agents. In: J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, and A. Goodman Gilman (eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ed. 9. pp. 1233-1287. New York: McGraw-Hill, 1996.
2. Bosslet, K., Czech, J., Lorenz, P., Sedlacek, H. H., Schuermann, M., and Seemann, G. Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br. J. Cancer, 65: 234-238, 1992.
3. Bosslet, K., Czech, J., and Hoffmann, D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res., 54: 2151-2159, 1994.
4. Bosslet, K., Czech, J., and Hoffmann, D. A novel one-step tumor-selective prodrug activation system. Tumor Targeting, 1: 45-50, 1995.
5. Houba, P. H. J., Leenders, R. G. G., Boven, E., Scheeren, J. W., Pinedo, H. M., and Haisma, H. J. Characterisation of novel anthracycline prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem. Pharmacol., 52: 455-463, 1996.
6. Senter, P. D., Wallace, P. M., Svensson, H. P., Vrudhula, V. M., Kerr, D. E., Hellström, I., and Hellström, K. E. Generation of cytotoxic agents by targeted enzymes. Bioconj. Chem., 4: 3-9, 1993.
7. Sinhababu, A. K., and Thakker, D. R. Prodrugs of anticancer agents. Adv. Drug Delivery Rev., 19: 241-273, 1996.
8. Linder, A., Friedel, G., Fritz, P., Kivistö, K. T., McClellan, M., and Toomes, H. The ex-vivo isolated, perfused human lung model: description and potential applications. Thorac. Cardiovasc. Surgeon, 44: 140-146, 1996.
9. Price, P., and Griffiths, J. Tumour pharmacokinetics? We do need to know. Lancet, 343: 1174-1175, 1994.
10. Johnston, M. R., Minchin, R., Shull, J. H., Thenot, J. P., McManus, B. M., Terrill, R., and Boyd, M. R. Isolated lung perfusion with Adriamycin. A preclinical study. Cancer (Phila.), 52: 404-409, 1983.
11. Minchin, R. F., Johnston, M. R., Schuller, H. M., Aiken, M. A., and Boyd, M. R. Pulmonary toxicity of doxorubicin administered by in situ isolated lung perfusion in dogs. Cancer (Phila.), 61: 1320-1325, 1988.
12. Minchin, R. F., Johnston, M. R., Aiken, M. A., and Boyd, M. R. Pharmacokinetics of doxorubicin in isolated lung of dogs and humans perfused in vivo. J. Pharmacol. Exp. Ther., 229: 193-198, 1984.
13. Baciewicz, F. A., Arredondo, M., Chaudhuri, B., Crist, K. A., Basilius, D., Bandyopadhyah, S., Thomford, N. R., and Chaudhuri, P. K. Pharmacokinetics and toxicity of isolated perfusion of lung with doxorubicin. J. Surg. Res., 50: 124-128, 1991.
14. Bongard, R. D., Roerig, D. L., Johnston, M. R., Linehan, J. H., and Dawson, C. A. Influence of temperature and plasma protein on doxorubicin uptake by isolated lungs. Drug Metab. Dispos., 21: 428-434, 1993.
15. Weksler, B., Lenert, J., Ng, B., and Burt, M. Isolated single lung perfusion with doxorubicin is effective in eradicating soft tissue sarcoma lung metastases in a rat model. J. Thorac. Cardiovasc. Surg., 107: 50-54, 1994.
16. Weksler, B., Ng, B., Lenert, J. T., and Burt, M. E. Isolated single-lung perfusion with doxorubicin is pharmacokinetically superior to intravenous injection. Ann. Thorac. Surg., 56: 209-214, 1993.
17. Ng, B., Hochwald, S. N., and Burt, M. E. Isolated lung perfusion with doxorubicin reduces cardiac and host toxicities associated with systemic administration. Ann. Thorac. Surg., 61: 969-972, 1996.
18. Mulvin, D. W., Howard, R. B., Mitchell, D. H., Noker, P. E., Kruse, C. A., Chu, H. D., Bunn, P. A., and Johnston, M. R. Secondary screening system for preclinical testing of human lung cancer therapies. J. Natl. Cancer Inst., 84: 31-37, 1992.
19. Cowen, M. E., Howard, R. B., Noker, P. E., Zeligman, B. E., Mulvin, D. W., Marcell, T., and Johnston, M. R. Dose-related doxorubicin effect in an orthotopic secondary lung cancer screen. J. Surg. Res., 56: 295-301, 1994.
20. Johnston, M. R., Minchin, R. F., and Dawson, C. A. Lung perfusion with chemotherapy in patients with unresectable metastatic sarcoma to the lung or diffuse bronchioloalveolar carcinoma. J. Thorac. Cardiovasc. Surg., 110: 368-373, 1995.
21. Jacquesy, J-C., Gesson, J-P., Monneret, C., Mondon, M., Renoux, B., Florent, J-C., Koch, M., Tillequin, F., Sedlacek, H. H., Gerken, M., Kolar C., Gaudel G., Bosslet K., Czech, J., Hoffmann, D., Seemann, G., Schorlemmer, H. U., and Dickneite, G. Prodrogues glycosylées, leur procédé de préparation et leurs utilisation. EPA no. 92401218.0, European Patent Office, Munich, Germany, 1992.
22. Gehrmann, M. C., Opper, M., Sedlacek, H. H., Bosslet, K., and Czech, J. Biochemical properties of recombinant human β-glucuronidase synthesized in baby hamster kidney cells. Biochem. J., 301: 821-828, 1994.
23. Lowry, O. H., Rosebrough, N. J., Fair, A. L., and Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
24. Sperker, B., Hu, P-C., and Herrmann, R. Identification of gene products of the P 1 operon of Mycoplasma pneumoniae. Mol. Microbiol., 5: 299-306, 1991.
25. Presant, C. A., Wolf, W., Waluch, V., Wiseman, C., Kennedy, P., Blayney, D., and Brechner, R. R. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet, 343: 1184-1187, 1994.
26. Leca, F., Marchiset-Leca, D., Noble, A., and Antonetti, M. New data on the pharmacokinetics of Adriamycin and its major metabolite, adriamycinol. Eur. J. Drug Metab. Pharmacokinet., 16: 107-111, 1991.
27. Warren, B. A. The vascular morphology of tumors. In: H. I. Peterson (ed.), Tumor Blood Circulation, pp. 1-48. Boca Raton: CRC Press, 1979.
28. Warren, B. A. Tumor angiogenesis. In: H. I. Peterson (ed.), Tumor Blood Circulation, pp. 49-76. Boca Raton: CRC Press, 1979.
29. Fishman, W. H., and Anlyan, A. J. The presence of high β-glucuronidase activity in cancer tissue. J. Biol. Chem., 169: 449-450, 1947.
30. Young, C. W., Yagoda, A., Bittar, E. S., Smith, S. W., Grabstald, H., and Whitmore, W. Therapeutic trial of aniline mustard in patients with advanced cancer: comparison of therapeutic response with cytochemical assessment of tumor cell β-glucuronidase activity. Cancer (Phila.), 38: 1887-1895, 1976.
31. Sperker, B., Mürdter, T. E., Schick, M., Eckhardt, K., Bosslet, K., and Kroemer H. K. Interindividual variability in expression and activity of human β-glucuronidase in liver and kidney. Consequences for drug metabolism. J. Pharmacol. Exp. Ther., in press, 1997.
32. Corralez-Hernández., J. J., González-Buitrago, Pastor-Encinas I., Garciá-Diez, L. C., and Miralles. J. M. Androgen environment and β-glucuronidase activity in the human kidney. Arch. Androl., 20: 185-191, 1988.
33. Haisma, H. J., van Muijen, M., Pinedo, H. M., and Boven, E. Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-β-glucuronidase conjugate in the specific treatment of cancer. Cell Biophys., 24: 185-192, 1994.
34. Speth, P. A. J., van Hoesel, Q. G. C. M., and Haanen, C. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet., 15: 15-31, 1988.